Miglustat

Miglustat, sold under the brand name Zavesca, is a medication used to treat type I Gaucher disease (GD1). It was developed by Oxford GlycoSciences and is marketed by Actelion. Miglustat has been approved in the EU, Japan, and Canada for treating progressive neurological complications in people with Niemann–Pick disease, type C (NPC). It was approved for medical use in the European Union in November 2002,[4][5] and for medical use in the United States in J... [wikipedia]